Stocks Health care ENTX
NASDAQ · Health careEntera Bio Ltd. (ENTX)
Entera Bio Ltd. brought in $0 of revenue over the twelve months to September 30, 2026, down 100.0% from a year earlier. It posted a net loss of $29.4M. In fiscal 2025 capital spending exceeded operating cash flow by $7.5M. At September 30, 2026 it held $265.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 6, 2026.
Key facts about Entera Bio Ltd.
- Net worth
- Entera Bio Ltd. has a market value (market cap) of $557.5M at the latest share price, and shareholders' equity of $274.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $42K (-76.8% year on year), with a net loss of $11.4M. Over the 12 months to September 30, 2026: revenue $0, net loss $29.4M.
- Cash flow
- In fiscal 2025 operations used $7.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Entera Bio Ltd.'s next report is expected around March 26, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Entera Bio Ltd. does
Entera Bio Ltd. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ENTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $42K | -$11.4M | $0.25 | -$7.5M |
| 2024 | $181K | -$9.5M | $0.25 | -$6.8M |
| 2023 | $0 | -$8.9M | $0.31 | -$7.3M |
| 2022 | $134K | -$13.1M | $0.45 | -$12.5M |
| 2021 | $571K | -$12.2M | $0.47 | -$9.1M |
| 2020 | $365K | -$11.2M | $0.67 | -$10.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ENTX ranks in Health care
Latest SEC filings
What Entera Bio Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026
- November 6, 2026
- October 30, 2026Passive stake (5% or more) SCHEDULE 13G
- October 27, 2026
- October 14, 2026Proxy statement DEF 14A
- October 6, 2026Executive or director change8-KEntera Bio appointed biopharmaceutical executive Laura Hamill to its board of directors effective December 1, 2026, succeeding Yonatan Malca.
- September 23, 2026Preliminary proxy statement PRE 14A
- August 21, 2026
- August 18, 2026
- August 7, 2026
Insider trades
What the people running Entera Bio Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 7, 2026 | Germano Geno JDirector | Received as pay | 25,014 | - |
| August 7, 2026 | Ellis SeanDirector | Received as pay | 20,034 | - |
| August 7, 2026 | Taitel HayaDirector | Received as pay | 20,790 | - |
| August 7, 2026 | Malca YonatanDirector | Received as pay | 22,815 | - |
| August 7, 2026 | Rubin Steven DDirector | Received as pay | 19,117 | - |
| July 14, 2026 | Toledano Miranda JayneChief Executive Officer, Director | Received as pay | 347,567 | - |
| July 14, 2026 | Toledano Miranda JayneChief Executive Officer, Director | Received as pay | 72,993 | - |
| May 7, 2026 | Burshtein GregoryChief of R&D | Received as pay | 87,591 | - |
Who owns ENTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Knoll Capital Management, LLC13G, passive with 2 related filers | 15% | November 20, 2024 |
| Bvf Partners L P13D, may seek influence with 9 related filers | 9.99% | August 4, 2026 |
| TCG Crossover GP III, LLC13G, passive with 2 related filers | 7.1% | August 4, 2026 |
| Vivo Opportunity, LLC13G, passive with 5 related filers | 6.9% | August 4, 2026 |
| Venrock Healthcare Capital Partners III, L.P.13G, passive with 6 related filers | 5.1% | October 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 27 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Knoll Capital Management, LLC | 5,881,879 | 0 |
| Bvf Inc | 2,425,000 | new |
| Siren, L.L.C. | 736,457 | new |
| Renaissance Technologies LLC | 368,847 | -104,595 |
| Parkman Healthcare Partners LLC | 274,497 | -14,173 |
| PNC Financial Services Group, Inc. | 273,031 | +263,031 |
| Seven Fleet Capital Management LP | 191,354 | -14,188 |
| HighTower Advisors, LLC | 74,573 | +37,743 |
| Schonfeld Strategic Advisors LLC | 58,871 | +3,648 |
| Two Sigma Securities, LLC | 48,593 | new |
| Signature Estate & Investment Advisors LLC | 47,328 | 0 |
| Citadel Advisors LLC | 38,804 | -206,773 |
| Jpmorgan Chase & Co | 40,883 | +33,733 |
| Geode Capital Management, LLC | 29,908 | +8,772 |
| Diadema Partners LP | 23,260 | 0 |
| XTX Topco Ltd | 20,559 | -111,063 |
| Gem Investment Advisors, LLC | 19,135 | 0 |
| Jane Street Group, LLC | 17,331 | -15,584 |
| Simplex Trading, LLC | 15,698 | new |
| UBS Group AG | 12,723 | +9,511 |
Insiders
11 insiders reported holding 2,312,049 shares in total, about $7.4M at the last price.
| Holder | Shares |
|---|---|
| Toledano Miranda JayneChief Executive Officer, Director | 847,135 |
| Lieberman Gerald MDirector | 338,454 |
| Ellis SeanDirector | 208,132 |
| Burshtein GregoryChief of R&D | 189,033 |
| Yaacov-Garbeli DanaChief Financial Officer | 171,441171,441 held indirectly |
| Galitzer HillelChief Operating Officer | 163,566 |
| Taitel HayaDirector | 119,269 |
| Malca YonatanDirector | 100,231 |
| Ostrov Gerald MDirector | 75,657 |
| Germano Geno JDirector | 65,014 |
Questions about ENTX
What does Entera Bio Ltd. do?
Entera Bio Ltd. is a company in the Health care sector, listed on NASDAQ as ENTX. Its shares trade on NASDAQ under the ticker ENTX.
What is Entera Bio Ltd.'s net worth?
Entera Bio Ltd. has a market value (market cap) of $557.5M at the latest share price, and shareholders' equity of $274.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Entera Bio Ltd. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $29.4M.
How much revenue does Entera Bio Ltd. make?
Over the twelve months to September 30, 2026 Entera Bio Ltd. reported revenue of $0. That is 100.0% less than a year earlier.
When did Entera Bio Ltd. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 6, 2026. It covers the period to September 30, 2026.
When is Entera Bio Ltd.'s next earnings report?
Entera Bio Ltd.'s next report is expected around March 26, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ENTX with
Follow ENTX
Get an email when Entera Bio Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Entera Bio Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.